Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis and Metrics

Xeris Biopharma Holdings

NASDAQ: XERS

$8.32 ▼ -0.09 (-1.07%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.43 Bn

P/E119.43

P/S4.55

Div. Yield0.00

Total Debt (Qtr)221.22 Mn

Revenue Growth (1y) (Qtr)38.27

Add ratio to table…

About

Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. The company offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing’s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis. Xeris is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous levothyroxine formulation leveraging its proprietary XeriSol technology.

Xeris generates revenue through the sale of its three commercial products: Recorlev, Gvoke, and Keveyis. Recorlev is a cortisol synthesis inhibitor approved for adults with Cushing's syndrome for whom surgery is not an option or has not been curative. Gvoke is a ready-to-use, liquid-stable glucagon product indicated for pediatric and adult patients with diabetes aged two years and above for the treatment of severe hypoglycemia. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis, a rare genetic neuromuscular disorder. The company serves patients through prescriptions written by healthcare providers and distributed via specialty pharmacies.

The company operates through the following segments:

• Recorlev segment includes the development and commercialization of Recorlev for the treatment of endogenous hypercortisolemia in adults with Cushing’s syndrome.

• Gvoke segment includes the development and commercialization of Gvoke for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes.

• Keveyis segment includes the development and commercialization of Keveyis for the treatment of Primary Periodic Paralysis.

• XP-8121 segment includes the development of once-weekly subcutaneous levothyroxine for the treatment of hypothyroidism, leveraging the proprietary XeriSol technology.

Xeris holds a differentiated position in the endocrine and rare disease therapeutic areas through its portfolio of commercial products and proprietary formulation technologies. The company competes with established pharmaceutical and specialty pharmaceutical companies in each of its therapeutic areas, including Corcept Therapeutics and Recordati for Cushing’s syndrome therapies, Amphastar and Zealand Pharma for ready-to-use glucagon products, and various generic manufacturers for Keveyis. Xeris leverages its proprietary non-aqueous XeriSol and XeriJect formulation technologies to create ready-to-use, room-temperature stable injectable formulations, providing a competitive advantage in drug delivery and patient convenience. The company’s intellectual property portfolio, including patents extending to 2040 for Recorlev and 2036 for Gvoke, supports its market position.

Xeris serves patients diagnosed with chronic endocrine and neurological conditions in the United States. The company’s customer base includes individuals with Cushing’s syndrome requiring pharmacologic intervention, patients with diabetes at risk of severe hypoglycemia, and individuals living with Primary Periodic Paralysis. Additionally, Xeris targets patients with hypothyroidism for its pipeline product XP-8121. The company collaborates with healthcare providers, specialty pharmacies, and third-party payors to ensure patient access to its therapies.

Investment Thesis

▲ Bull case

Xeris Biopharma Holdings is positioned for sustained multi-year growth driven by Recorlev's accelerating adoption curve, with Q1 2026 revenue nearly doubling to $49.8 million on 95% year-over-year growth fueled by record new patient starts and referrals, particularly a significant rebound in March after typical Q1 payer resets, indicating underlying demand is stronger than headline quarterly volatility suggests and the company's expanded commercial infrastructure of 80 reps targeting 12,000 physicians is only beginning to scale, with management noting the full impact of this expansion will materialize in the second half of 2026 and continue delivering benefits well into the future as the sales force reaches full productivity and captures more of the undiagnosed hypercortisolemia population.
The pipeline catalyst of XP-8121 represents a significant de-risked near-term value inflection point, with Phase III initiation on track for later in 2026 leveraging existing XeriSol formulation technology from Gvoke and deep endocrinology commercial expertise, addressing a large unmet need in millions of hypothyroid patients struggling with GI absorption issues, and presenting four medical conference abstracts this quarter alone to build physician awareness ahead of a comprehensive fall program review, all while management explicitly ties capital allocation to growth opportunities and views the asset as a $1 billion to $3 billion peak sales opportunity, signaling confidence in both clinical and commercial success beyond mere trial initiation.
Financial momentum is translating into meaningful operating leverage and balance sheet strength, with Q1 2026 adjusted EBITDA improving by $10.7 million year-over-year to $15.1 million and net income turning positive at $2.2 million versus a $9.2 million loss in the prior year, driven by 87% gross margin expansion from favorable product mix and disciplined scaling of SG&A at 21% growth aligned with revenue acceleration, demonstrating that the company is not merely growing top line but doing so profitably, which supports the raised 2026 revenue guidance of $380–$390 million (over 30% growth) and provides flexibility for reinvestment or balance sheet optimization as profitability continues to improve through the year.

Xeris Biopharma Holdings is positioned for sustained multi-year growth driven by Recorlev's accelerating adoption curve, with Q1 2026 revenue nearly doubling to $49.8 million on 95% year-over-year growth fueled by record new patient starts and referrals, particularly a significant rebound in March after typical Q1 payer resets, indicating underlying demand is stronger than headline quarterly volatility suggests and the company's expanded commercial infrastructure of 80 reps targeting 12,000 physicians is only beginning to scale, with management noting the full impact of this expansion will materialize in the second half of 2026 and continue delivering benefits well into the future as the sales force reaches full productivity and captures more of the undiagnosed hypercortisolemia population.
The pipeline catalyst of XP-8121 represents a significant de-risked near-term value inflection point, with Phase III initiation on track for later in 2026 leveraging existing XeriSol formulation technology from Gvoke and deep endocrinology commercial expertise, addressing a large unmet need in millions of hypothyroid patients struggling with GI absorption issues, and presenting four medical conference abstracts this quarter alone to build physician awareness ahead of a comprehensive fall program review, all while management explicitly ties capital allocation to growth opportunities and views the asset as a $1 billion to $3 billion peak sales opportunity, signaling confidence in both clinical and commercial success beyond mere trial initiation.
Financial momentum is translating into meaningful operating leverage and balance sheet strength, with Q1 2026 adjusted EBITDA improving by $10.7 million year-over-year to $15.1 million and net income turning positive at $2.2 million versus a $9.2 million loss in the prior year, driven by 87% gross margin expansion from favorable product mix and disciplined scaling of SG&A at 21% growth aligned with revenue acceleration, demonstrating that the company is not merely growing top line but doing so profitably, which supports the raised 2026 revenue guidance of $380–$390 million (over 30% growth) and provides flexibility for reinvestment or balance sheet optimization as profitability continues to improve through the year.

▼ Bear case

Gvoke's persistent weakness in the Medicare channel, which management acknowledged was hit harder than competitors like BAQSIMI due to its unfavorable channel mix, reveals a structural vulnerability beyond typical Q1 payer resets, as higher out-of-pocket costs from plan changes directly reduced prescription fills and the company conceded recovery depends on beneficiaries hitting catastrophic coverage later in the year, indicating the rebound is contingent on patient financial thresholds rather than renewed demand strength, and with the vast majority of the 15 million eligible patients still lacking ready-to-use glucagon rescue therapy, the lack of meaningful growth in Gvoke despite this large addressable market suggests ongoing pricing, access, or reimbursement headwinds that may not fully dissipate even with seasonal recovery.
The commercial expansion for Recorlev, while presented as a growth driver, may be delivering diminishing returns, as management admitted the real impact of the expanded 80-rep force targeting 12,000 physicians will not be felt until 6 to 9 months post-hire (second half of 2026), and the contribution from this investment was already embedded in the original guidance range, meaning the raised low end of $380–$390 million reflects only modest upside from execution beyond plan, raising concerns that the sales force scaling is ahead of sustainable organic demand and could lead to elevated SG&A pressure without proportional revenue contribution if physician adoption or diagnosis rates do not accelerate as expected.
Pipeline optimism around XP-8121 carries significant execution risk masked by disciplined pacing, as the company is delaying Phase III initiation not only for clinical readiness but until the go-to-market commercial presentation is fully prepared, indicating potential lack of confidence in the asset's standalone differentiation or market access strategy, and while R&D spending is rising 13% to support the program, the lack of disclosed trial design details or interim data beyond early-phase signals leaves investors reliant on management's assertion of a $1 billion to $3 billion opportunity without clear visibility into competitive positioning, dosing advantages, or payer receptiveness for a once-weekly subcutaneous hypothyroidism therapy in a crowded market with established alternatives.

Gvoke's persistent weakness in the Medicare channel, which management acknowledged was hit harder than competitors like BAQSIMI due to its unfavorable channel mix, reveals a structural vulnerability beyond typical Q1 payer resets, as higher out-of-pocket costs from plan changes directly reduced prescription fills and the company conceded recovery depends on beneficiaries hitting catastrophic coverage later in the year, indicating the rebound is contingent on patient financial thresholds rather than renewed demand strength, and with the vast majority of the 15 million eligible patients still lacking ready-to-use glucagon rescue therapy, the lack of meaningful growth in Gvoke despite this large addressable market suggests ongoing pricing, access, or reimbursement headwinds that may not fully dissipate even with seasonal recovery.
The commercial expansion for Recorlev, while presented as a growth driver, may be delivering diminishing returns, as management admitted the real impact of the expanded 80-rep force targeting 12,000 physicians will not be felt until 6 to 9 months post-hire (second half of 2026), and the contribution from this investment was already embedded in the original guidance range, meaning the raised low end of $380–$390 million reflects only modest upside from execution beyond plan, raising concerns that the sales force scaling is ahead of sustainable organic demand and could lead to elevated SG&A pressure without proportional revenue contribution if physician adoption or diagnosis rates do not accelerate as expected.
Pipeline optimism around XP-8121 carries significant execution risk masked by disciplined pacing, as the company is delaying Phase III initiation not only for clinical readiness but until the go-to-market commercial presentation is fully prepared, indicating potential lack of confidence in the asset's standalone differentiation or market access strategy, and while R&D spending is rising 13% to support the program, the lack of disclosed trial design details or interim data beyond early-phase signals leaves investors reliant on management's assertion of a $1 billion to $3 billion opportunity without clear visibility into competitive positioning, dosing advantages, or payer receptiveness for a once-weekly subcutaneous hypothyroidism therapy in a crowded market with established alternatives.

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	87.22 Bn	102.28	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	39.60 Bn	23.19	2.28	16.63 Bn
3	ZTS	Zoetis Inc.	31.46 Bn	11.90	3.31	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	26.49 Bn	-10.03	0.57	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.03 Bn	17.89	7.27	-
6	UPC	Universe Pharmaceuticals INC	23.03 Bn	0.00	1.29	7.15 Bn
7	VTRS	Viatris Inc	20.90 Bn	-67.34	1.43	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.50 Bn	26.18	5.64	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password